Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015

El sarcoma de Kaposi es un tumor angioproliferativo poco frecuente etiológicamente vinculado al virus herpes humano tipo 8 y asociado a inmunosupresión. Clínicamente se reconocen 4 subtipos, en los cuales observamos que pueden presentar compromiso a nivel cutáneo y/o visceral. Algunos de ellos puede...

Full description

Autores:
Díaz Bueno, Pedro Antonio
Tipo de recurso:
Fecha de publicación:
2021
Institución:
Universidad Autónoma de Bucaramanga - UNAB
Repositorio:
Repositorio UNAB
Idioma:
spa
OAI Identifier:
oai:repository.unab.edu.co:20.500.12749/13926
Acceso en línea:
http://hdl.handle.net/20.500.12749/13926
Palabra clave:
Dermatology
Medical sciences
Health sciences
Kaposi's sarcoma
Angioproliferative tumor
Neoplasms
Biometrics
Dermatología
Ciencias médicas
Medicina
Neoplasmas
Biometría
Ciencias de la salud
Sarcoma de kaposi
Tumor angioproliferativo
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UNAB2_1e3e5c195ac57aad3f4d0f127f9d95d6
oai_identifier_str oai:repository.unab.edu.co:20.500.12749/13926
network_acronym_str UNAB2
network_name_str Repositorio UNAB
repository_id_str
dc.title.spa.fl_str_mv Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
dc.title.translated.spa.fl_str_mv 5-year survival analysis of patients with kaposi sarcoma in the metropolitan area of ​​Bucaramanga between the years 2000-2015
title Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
spellingShingle Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
Dermatology
Medical sciences
Health sciences
Kaposi's sarcoma
Angioproliferative tumor
Neoplasms
Biometrics
Dermatología
Ciencias médicas
Medicina
Neoplasmas
Biometría
Ciencias de la salud
Sarcoma de kaposi
Tumor angioproliferativo
title_short Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
title_full Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
title_fullStr Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
title_full_unstemmed Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
title_sort Análisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-2015
dc.creator.fl_str_mv Díaz Bueno, Pedro Antonio
dc.contributor.advisor.none.fl_str_mv Uribe Pérez, Claudia Janeth
Serrano Gómez, Sergio Eduardo
dc.contributor.author.none.fl_str_mv Díaz Bueno, Pedro Antonio
dc.contributor.cvlac.spa.fl_str_mv Uribe Pérez, Claudia Janeth [0000267848]
Serrano Gómez, Sergio Eduardo [0001521095]
dc.contributor.orcid.spa.fl_str_mv Serrano Gómez, Sergio Eduardo [0000-0001-6418-7116]
dc.contributor.researchgate.spa.fl_str_mv Uribe Pérez, Claudia Janeth [Claudia-Janeth-Uribe-Perez-2157369946]
dc.subject.keywords.spa.fl_str_mv Dermatology
Medical sciences
Health sciences
Kaposi's sarcoma
Angioproliferative tumor
Neoplasms
Biometrics
topic Dermatology
Medical sciences
Health sciences
Kaposi's sarcoma
Angioproliferative tumor
Neoplasms
Biometrics
Dermatología
Ciencias médicas
Medicina
Neoplasmas
Biometría
Ciencias de la salud
Sarcoma de kaposi
Tumor angioproliferativo
dc.subject.lemb.spa.fl_str_mv Dermatología
Ciencias médicas
Medicina
Neoplasmas
Biometría
dc.subject.proposal.spa.fl_str_mv Ciencias de la salud
Sarcoma de kaposi
Tumor angioproliferativo
description El sarcoma de Kaposi es un tumor angioproliferativo poco frecuente etiológicamente vinculado al virus herpes humano tipo 8 y asociado a inmunosupresión. Clínicamente se reconocen 4 subtipos, en los cuales observamos que pueden presentar compromiso a nivel cutáneo y/o visceral. Algunos de ellos pueden tener un crecimiento lento, localizado o indolente, pero pueden llegar a diseminarse y/o crecer rápidamente y causar morbilidad y mortalidad significativa. Desde su primer reporte en 1872, observamos que el sarcoma de Kaposi presentó un aumento las tasas de incidencia asociado a la epidemia del VIH hacia los años 80´s, con posterior descenso con el advenimiento de la terapia antirretroviral(1,2). Actualmente se reconocen tasas de supervivencia a 5 años que van desde el 38% al 72% de acuerdo a si el compromiso es extenso o localizado, respectivamente(2). Sin embargo, en Colombia, y específicamente en Santander, no se ha encontrado hasta la fecha ningún estudio que aporte datos locales sobre el comportamiento de este tumor en nuestra población. Por lo anterior, teniendo en cuenta la importancia de esta patología, la falta de estudios a nivel nacional que caractericen o demuestren una asociación entre las variables clínicas con la sobrevida y el impacto de la obtención de estos datos y su aplicabilidad en los modelos de atención, promoción y prevención de tumores malignos, se decide realizar este estudio retrospectivo tomando los datos del registro poblacional de cáncer del área metropolitana de Bucaramanga de los años, con el objetivo de determinar las variables sociodemográficas que impactan en la sobrevida del paciente, obteniendo datos importantes como la incidencia del sarcoma de Kaposi en el área metropolitana, la tasa de sobrevida de esta población, el grado de asociación con las diferentes variables entre otros.
publishDate 2021
dc.date.accessioned.none.fl_str_mv 2021-08-19T22:07:23Z
dc.date.available.none.fl_str_mv 2021-08-19T22:07:23Z
dc.date.issued.none.fl_str_mv 2021
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.local.spa.fl_str_mv Tesis
dc.type.redcol.none.fl_str_mv http://purl.org/redcol/resource_type/TM
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12749/13926
dc.identifier.instname.spa.fl_str_mv instname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional UNAB
dc.identifier.repourl.spa.fl_str_mv repourl:https://repository.unab.edu.co
url http://hdl.handle.net/20.500.12749/13926
identifier_str_mv instname:Universidad Autónoma de Bucaramanga - UNAB
reponame:Repositorio Institucional UNAB
repourl:https://repository.unab.edu.co
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. Kaposi M. Idiopathisches multiples Pigmentsarkom. Docent an der Univ Wien. 1872;1(27):265–73
2. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Prim [Internet]. 2019;5(1). Available from: http://dx.doi.org/10.1038/s41572-019-0060-9
3. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med. 1996;2(8):925–7
4. Chan RKW, Chio MTW, Koh Y. Manifestaciones cutáneas de infección por el VIH [Internet]. Cuarta edi. Bolognia J, Schaffer J, Cerroni L, editors. Dermatología. Madrid: Elsevier Espa8#241;a, S.L.U.; 2018. 1364–1382 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00078-4
5. Kaye KM. Virus herpes asociado al sarcoma de Kaposi (virus herpes humano de tipo 8) [Internet]. Octava. Bennett J, Dolin R, Blaser M, editors. Mandell, Douglas y Bennett. Enfermedades infecciosas. Principios y práctica. Elsevier Espa8#241;a, S.L.U.; 2016. 1868–1873 p. Available from: http://dx.doi.org/10.1016/B978-84-9022-917-0/00143-8
6. Cattani P, Cerimele F, Porta D, Graffeo R, Ranno S, Marchetti S, et al. Agespecific seroprevalence of human herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect [Internet]. 2003 Apr 1 [cited 2020 Jul 7];9(4):274–9. Available from: https://pubmed.ncbi.nlm.nih.gov/12667236/
7. Angeloni A, Heston L, Uccini S, Sirianni MC, Cottoni F, Masala MV, et al. High Prevalence of Antibodies to Human Herpesvirus 8 in Relatives of Patients with Classic Kaposi’s Sarcoma from Sardinia. J Infect Dis [Internet]. 1998 Jun [cited 2020 Jul 7];177(6):1715–8. Available from: https://pubmed.ncbi.nlm.nih.gov/9607855/
8. Mohanna S, Ferrufino JC, Sanchez J, Bravo F, Gotuzzo E. Epidemiological and clinical characteristics of classic Kaposi’s sarcoma in Peru. J Am Acad Dermatol [Internet]. 2005 [cited 2020 Jul 7];53(3):435–41. Available from: https://pubmed.ncbi.nlm.nih.gov/16112349/
9. AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clin Infect Dis. 2017;65(8):1316–26.
10. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al. SEER Cancer Statistics Review 1975-2007 National Cancer Institute SEER Cancer Statistics Review 1975-2007 National Cancer Institute. Cancer. 2019.
11. Instituto Nacional De Salud. Boletín Epidemiológico Semanal -BES-, Colombia 2019. Ministerio de salud. 2019.
12. Jiménez K, Martínez JD, Hernández G, Garzón MA, Hormaza N, Lizarazo JI, et al. Three varieties of Kaposi’s sarcoma with gastrointestinal involvement. Rev Colomb Gastroenterol. 2015;30(3):342–6
13. Downing C, Mendoza N, Sra K. 80 - Virus del herpes humanos [Internet]. Fourth Edi. DermatologÃ-a. Elsevier Espa8#241;a, S.L.U.; 2019. 1400–1424 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00080-2
14. Sternbach G, Varon J. Moritz Kaposi: Idiopathic pigmented sarcoma of the skin. J Emerg Med [Internet]. 1995 [cited 2020 Jul 8];13(5):671–4. Available from: https://pubmed.ncbi.nlm.nih.gov/8530789/
15. North PE. Neoplasias y proliferaciones seudoneoplásicas vasculares [Internet]. Cuarta edi. Bolognia J, Schaffer J, Cerroni L, editors. Dermatología. Madrid: Elsevier Espa8#241;a, S.L.U.; 2018. 2020–2049 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00114-5
16. Antman K, Chang Y. Kaposi ’s Sarcoma. N Engl J Med. 2000;342(14):1027– 38
17. Cai Q, Verma SC, Lu J, Robertson ES. Molecular Biology of Kaposi’s Sarcoma-associated Herpesvirus and Related Oncogenesis [Internet]. 1st ed. Vol. 78, Advances in Virus Research. Elsevier Inc.; 2010. 87–142 p. Available from: http://dx.doi.org/10.1016/B978-0-12-385032-4.00003-3
18. Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol. 2019;58(5):538–42
19. Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation [Internet]. Vol. 42, Seminars in Oncology. W.B. Saunders; 2015 [cited 2020 Jul 12]. p. 247–57. Available from: https://pubmed.ncbi.nlm.nih.gov/25843729/
20. Corey C. Virology, epidemiology, and transmission of human herpesvirus 8 infection - UpToDate [Internet]. Uptodate. [cited 2020 Jul 12]. Available from: https://www-uptodate-com.aure.unab.edu.co/contents/virology-epidemiologyand-transmission-of-human-herpesvirus-8-infection?search=sarcoma de kaposi&topicRef=7726&source=see_link
21. Krown S, Chadha J. Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis - UpToDate [Internet]. Uptodate. 2019 [cited 2020 Jul 12]. Available from: https://www-uptodatecom.aure.unab.edu.co/contents/classic-kaposi-sarcoma-epidemiology-riskfactors-pathology-and-molecular-pathogenesis?search=sarcoma de kaposi&topicRef=7729&source=see_link
22. Schneider JW, Dittmer DP. Diagnosis and Treatment of Kaposi Sarcoma [Internet]. Vol. 18, American Journal of Clinical Dermatology. Springer International Publishing; 2017 [cited 2020 Jul 8]. p. 529–39. Available from: /pmc/articles/PMC5509489/?report=abstract
23. Kandemir NO, Gun BD, Bahadir B, Yurdakan G, Ozdemir N, Karadayi N, et al. C-Kit (CD117) expression in classic Kaposi’s sarcoma: Experimental dermatology. Clin Exp Dermatol [Internet]. 2010 Jul [cited 2020 Jul 12];35(5):525–30. Available from: https://pubmed.ncbi.nlm.nih.gov/19874361
24. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol [Internet]. 2008 May [cited 2020 Jul 7];21(5):572–82. Available from: https://pubmed.ncbi.nlm.nih.gov/18376387/
25. Requena C, Alsina M, Morgado-Carrasco D, Cruz J, Sanmartín O, SerraGuillén C, et al. Kaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment. Actas Dermosifiliogr [Internet]. 2018;109(10):878–87. Available from: https://doi.org/10.1016/j.ad.2018.06.013
26. Montagnino G, Bencini PL, Tarantino A, Caputo R, Ponticelli C. Clinical features and course of kaposi’s sarcoma in kidney transplant patients: Report of 13 cases. Am J Nephrol [Internet]. 1994 [cited 2020 Jul 15];14(2):121–6. Available from: https://pubmed.ncbi.nlm.nih.gov/8080004/
27. Shepherd FA, Maher E, Cardella C, Cole E, Greig P, Wade JA, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol [Internet]. 1997 [cited 2020 Jul 15];15(6):2371–7. Available from: https://pubmed.ncbi.nlm.nih.gov/9196152
28. Groopman J. AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis - UpToDate [Internet]. Uptodate. 2018 [cited 2020 Jul 15]. Available from: https://www-uptodate-com.aure.unab.edu.co/contents/aids-relatedkaposi-sarcoma-clinical-manifestations-and-diagnosis?search=sarcoma de kaposi&topicRef=7729&source=see_link
29. Ackerman AB. Subtle clues to diagnosis by conventional microscopy. The patch stage of Kaposi’s sarcoma. Am J Dermatopathol [Internet]. 1979 [cited 2020 Jul 18];1(2):165–72. Available from: https://pubmed.ncbi.nlm.nih.gov/549492/
30. O’Donnell PJ, Pantanowitz L, Grayson W. Unique histologic variants of cutaneous Kaposi sarcoma. Am J Dermatopathol [Internet]. 2010 May [cited 2020 Jul 18];32(3):244–50. Available from: https://pubmed.ncbi.nlm.nih.gov/20075709/
31. Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol [Internet]. 2008 [cited 2020 Jul 18];3(1). Available from: https://pubmed.ncbi.nlm.nih.gov/18655700/
32. Pak F, Pyakural P, Kokhaei P, Kaaya E, Pourfathollah AA, Selivanova G, et al. HHV-8/KSHV during the development of Kaposi’s sarcoma: Evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol [Internet]. 2005 Jan [cited 2020 Jul 18];32(1):21–7. Available from: https://pubmed.ncbi.nlm.nih.gov/15660651/
33. Bishop BN, Lynch DT. Cancer, Kaposi Sarcoma [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30521260
34. Bishop BN, Lynch DT. Cancer, Kaposi Sarcoma [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2020 Nov 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30521260
35. Marušić Z, Billings SD. Histopathology of Spindle Cell Vascular Tumors [Internet]. Vol. 10, Surgical Pathology Clinics. W.B. Saunders; 2017 [cited 2020 Aug 18]. p. 345–66. Available from: https://pubmed.ncbi.nlm.nih.gov/28477885
36. Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of african children: Evidence for at least 2 patterns of KSHV transmission. J Infect Dis [Internet]. 2009 Aug 1 [cited 2020 Aug 18];200(3):430–8. Available from: /pmc/articles/PMC3975590/?report=abstract
37. Moosa MR. Kaposi’s sarcoma in kidney transplant recipients: A 23-year experience. QJM - Mon J Assoc Physicians [Internet]. 2005 Mar [cited 2020 Aug 18];98(3):205–14. Available from: https://pubmed.ncbi.nlm.nih.gov/15728402
38. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS [Internet]. 2009 Aug 24 [cited 2020 Aug 18];23(13):1701–6. Available from: https://pubmed.ncbi.nlm.nih.gov/19550283
39. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy. Cancer [Internet]. 2010 Aug 15 [cited 2020 Aug 18];116(16):3969–77. Available from: https://pubmed.ncbi.nlm.nih.gov/20564162
40. Delyon J, Bizot A, Battistella M, Madelaine I, Vercellino L, Lebbé C. PD-1 blockade with nivolumab in endemic Kaposi sarcoma [Internet]. Vol. 29, Annals of Oncology. Oxford University Press; 2018 [cited 2020 Aug 18]. p. 1067–9. Available from: https://pubmed.ncbi.nlm.nih.gov/29324995
41. Lundgren JD, Melbye M, Pedersen C, Rosenberg PS, Gerstoft J. Changing patterns of kaposi’s sarcoma in danish acquired immunodeficiency syndrome patients with complete follow-up. Am J Epidemiol [Internet]. 1995 Apr 1 [cited 2020 Nov 18];142(7):652–8. Available from: https://pubmed.ncbi.nlm.nih.gov/7702040/
42. Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi’s sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol [Internet]. 1993 [cited 2020 Nov 18];28(3):371– 95. Available from: https://pubmed.ncbi.nlm.nih.gov/8445054
43. Franceschi S, Arniani S, Balzi D, Geddes M. Survival of classic Kaposi’s sarcoma and risk of second cancer. Br J Cancer. 1996;74(11):1812–4.
44. Tam HK, Zhang ZF, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer. 2002;98(6):916–22.
45. Lodi S, Guiguet M, Costagliola D, Fisher M, De Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102(11):784–92
46. Sen F, Tambas M, Ciftci R, Toz B, Kilic L, Bozbey HU, et al. Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma. J Dermatolog Treat. 2016;27(3):275–7.
47. Royse KE, El Chaer F, Amirian ES, Hartman C, Krown SE, Uldrick TS, et al. Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. PLoS One. 2017;12(8):1–12
48. Vivek K, Parita S, Mohit G, Arsalan T, Abhinav B. Racial disparities in incidence & survival of Kaposi’s sarcoma in the United States Vivek. Indian J Med Res [Internet]. 2019;354–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23144490
49. Saldarriaga-Cantillo A, Bravo LE, Londoño Ó, García LS, Collazos P. Epidemiological surveillance of the HIV/AIDS complex through the analysis of trends in the incidence of Kaposi’s sarcoma in Cali, Colombia. Colomb Med. 2012;43(4):273–80
50. Levi F. Cancer incidence in five continents, vol. VI. Vol. 29, European Journal of Cancer. 1993. 2315–2319 p
51. Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Collazos T, et al. Reliable information for cancer control in Cali, Colombia. Colomb Med [Internet]. 2018 [cited 2021 Jun 8];49(1):23–34. Available from: /pmc/articles/PMC6018818/
52. Mohanna S, Maco V, Bravo F, Gotuzzo E. Epidemiology and clinical characteristics of classic Kaposi’s sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: A critical review of an old disease [Internet]. Vol. 9, International Journal of Infectious Diseases. Elsevier; 2005 [cited 2020 Jul 7]. p. 239–50. Available from: https://pubmed.ncbi.nlm.nih.gov/16095940
53. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol. 2008;21(5):572–82
54. Oncologia C. Survival and Prognostic Factors of Kaposi ’ s Sarcoma Patients Treated at a High Complexity Oncology Care Center. 2020;66(3).
55. Klingenberg RE, Esser S, Brockmeyer NH, Michalik C, Skaletz-Rorowski A, Potthoff A. Profile of Kaposi sarcoma patients in the competence network HIV/AIDS. Hautarzt. 2018;69(2):143–8.
56. Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S, et al. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32(5):409–14
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.local.spa.fl_str_mv Abierto (Texto Completo)
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.*.fl_str_mv Atribución-NoComercial-SinDerivadas 2.5 Colombia
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-SinDerivadas 2.5 Colombia
eu_rights_str_mv openAccess
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.coverage.spatial.spa.fl_str_mv Bucaramanga (Santander, Colombia)
dc.coverage.temporal.spa.fl_str_mv 2000-2015
dc.coverage.campus.spa.fl_str_mv UNAB Campus Bucaramanga
dc.publisher.grantor.spa.fl_str_mv Universidad Autónoma de Bucaramanga UNAB
dc.publisher.faculty.spa.fl_str_mv Facultad Ciencias de la Salud
dc.publisher.program.spa.fl_str_mv Especialización en Dermatología
institution Universidad Autónoma de Bucaramanga - UNAB
bitstream.url.fl_str_mv https://repository.unab.edu.co/bitstream/20.500.12749/13926/3/license.txt
https://repository.unab.edu.co/bitstream/20.500.12749/13926/1/2021_Tesis_Pedro_Diaz_Bueno.pdf
https://repository.unab.edu.co/bitstream/20.500.12749/13926/2/2021_Licencia_Pedro_Diaz_Bueno.pdf
https://repository.unab.edu.co/bitstream/20.500.12749/13926/4/2021_Tesis_Pedro_Diaz_Bueno.pdf.jpg
https://repository.unab.edu.co/bitstream/20.500.12749/13926/5/2021_Licencia_Pedro_Diaz_Bueno.pdf.jpg
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
4edca90cce0e81169e3ecfd61ee3d8b9
0ea3378defa5bdb0a3f5588784c69c56
fcf0ea29c4b8ed925a8c493087419146
6389e2ad47659de81a755bc3119e495c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional | Universidad Autónoma de Bucaramanga - UNAB
repository.mail.fl_str_mv repositorio@unab.edu.co
_version_ 1828219747934666752
spelling Uribe Pérez, Claudia Janethccc0f1cf-be6c-4b77-a985-d1713f5efc36-1Serrano Gómez, Sergio Eduardo9ea84e2c-e5e0-415b-9e16-308be15c2afc-1Díaz Bueno, Pedro Antonio28538fca-b0d0-4d65-b75a-f08c44f9c15f-1Uribe Pérez, Claudia Janeth [0000267848]Serrano Gómez, Sergio Eduardo [0001521095]Serrano Gómez, Sergio Eduardo [0000-0001-6418-7116]Uribe Pérez, Claudia Janeth [Claudia-Janeth-Uribe-Perez-2157369946]Bucaramanga (Santander, Colombia)2000-2015UNAB Campus Bucaramanga2021-08-19T22:07:23Z2021-08-19T22:07:23Z2021http://hdl.handle.net/20.500.12749/13926instname:Universidad Autónoma de Bucaramanga - UNABreponame:Repositorio Institucional UNABrepourl:https://repository.unab.edu.coEl sarcoma de Kaposi es un tumor angioproliferativo poco frecuente etiológicamente vinculado al virus herpes humano tipo 8 y asociado a inmunosupresión. Clínicamente se reconocen 4 subtipos, en los cuales observamos que pueden presentar compromiso a nivel cutáneo y/o visceral. Algunos de ellos pueden tener un crecimiento lento, localizado o indolente, pero pueden llegar a diseminarse y/o crecer rápidamente y causar morbilidad y mortalidad significativa. Desde su primer reporte en 1872, observamos que el sarcoma de Kaposi presentó un aumento las tasas de incidencia asociado a la epidemia del VIH hacia los años 80´s, con posterior descenso con el advenimiento de la terapia antirretroviral(1,2). Actualmente se reconocen tasas de supervivencia a 5 años que van desde el 38% al 72% de acuerdo a si el compromiso es extenso o localizado, respectivamente(2). Sin embargo, en Colombia, y específicamente en Santander, no se ha encontrado hasta la fecha ningún estudio que aporte datos locales sobre el comportamiento de este tumor en nuestra población. Por lo anterior, teniendo en cuenta la importancia de esta patología, la falta de estudios a nivel nacional que caractericen o demuestren una asociación entre las variables clínicas con la sobrevida y el impacto de la obtención de estos datos y su aplicabilidad en los modelos de atención, promoción y prevención de tumores malignos, se decide realizar este estudio retrospectivo tomando los datos del registro poblacional de cáncer del área metropolitana de Bucaramanga de los años, con el objetivo de determinar las variables sociodemográficas que impactan en la sobrevida del paciente, obteniendo datos importantes como la incidencia del sarcoma de Kaposi en el área metropolitana, la tasa de sobrevida de esta población, el grado de asociación con las diferentes variables entre otros.1. RESUMEN DEL PROYECTO: ......................................................................... 7 2. DESCRIPCIÓN DEL PROYECTO ...................................................................... 9 2.1 Planteamiento del problema y justificación .............................................. 9 2.2 Marco teórico.............................................................................................. 10 2.2.1 Definición ............................................................................................... 10 2.2.2 Epidemiología ........................................................................................ 10 2.2.3 Fisiopatogenia ....................................................................................... 13 2.2.4 Características clínicas .......................................................................... 14 2.2.5 Diagnóstico ............................................................................................ 16 2.2.6 Pronóstico y prevención ......................................................................... 17 2.2.7 Tratamiento ............................................................................................ 19 2.3 Estado del arte ........................................................................................... 20 2.4 Objetivos del estudio ................................................................................. 23 2.4.1 Objetivo general ..................................................................................... 23 2.4.2 Objetivos específicos ............................................................................. 23 2.5 Metodología ................................................................................................ 23 2.5.1. Criterios de inclusión ............................................................................. 23 2.5.2. Criterios de exclusión: ........................................................................... 23 2.5.3. Cálculo de tamaño de muestra y muestreo: ......................................... 23 2.5.4. Mecanismo de recolección de la información ....................................... 23 2.5.6 Definición de variables ........................................................................... 24 2.6 Plan de análisis de datos: ......................................................................... 26 2.7 Consideraciones éticas: ............................................................................ 27 3. RESULTADOS ............................................................................................... 28 3.1 Descripción de la cohorte ......................................................................... 28 3.2 Desenlaces ................................................................................................. 31 3.3 Análisis de supervivencia ......................................................................... 32 4. DISCUSIÓN .................................................................................................... 39 5. CONCLUSIONES ........................................................................................... 41 6. BIBLIOGRAFÍA .............................................................................................. 42EspecializaciónKaposi's sarcoma is a rare angioproliferative tumor etiologically linked to human herpes virus type 8 and associated with immunosuppression. Clinically, 4 subtypes are recognized, in which we observe that they may present skin and / or visceral involvement. Some of them may be slow, localized or indolent growth, but they can spread and / or grow rapidly and cause significant morbidity and mortality. Since its first report in 1872, we observed that Kaposi's sarcoma presented an increase in the incidence rates associated with the HIV epidemic towards the 1980s, with a subsequent decrease with the advent of antiretroviral therapy (1,2). Currently, 5-year survival rates ranging from 38% to 72% are recognized according to whether the involvement is extensive or localized, respectively (2). However, in Colombia, and specifically in Santander, no study has been found to date that provides local data on the behavior of this tumor in our population. Therefore, taking into account the importance of this pathology, the lack of studies at the national level that characterize or demonstrate an association between clinical variables with survival and the impact of obtaining these data and their applicability in care models , promotion and prevention of malignant tumors, it was decided to carry out this retrospective study taking data from the population registry of cancer of the metropolitan area of ​​Bucaramanga of the years, with the aim of determining the sociodemographic variables that impact on the survival of the patient, obtaining important data such as the incidence of Kaposi's sarcoma in the metropolitan area, the survival rate of this population, the degree of association with the different variables, among others.Modalidad Presencialapplication/pdfspahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Abierto (Texto Completo)info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Atribución-NoComercial-SinDerivadas 2.5 ColombiaAnálisis de supervivencia a 5 años de pacientes con Sarcoma de Kaposi del área metropolitana de Bucaramanga entre los años 2000-20155-year survival analysis of patients with kaposi sarcoma in the metropolitan area of ​​Bucaramanga between the years 2000-2015Especialista en DermatologíaUniversidad Autónoma de Bucaramanga UNABFacultad Ciencias de la SaludEspecialización en Dermatologíainfo:eu-repo/semantics/masterThesisTesishttp://purl.org/redcol/resource_type/TMDermatologyMedical sciencesHealth sciencesKaposi's sarcomaAngioproliferative tumorNeoplasmsBiometricsDermatologíaCiencias médicasMedicinaNeoplasmasBiometríaCiencias de la saludSarcoma de kaposiTumor angioproliferativo1. Kaposi M. Idiopathisches multiples Pigmentsarkom. Docent an der Univ Wien. 1872;1(27):265–732. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Prim [Internet]. 2019;5(1). Available from: http://dx.doi.org/10.1038/s41572-019-0060-93. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med. 1996;2(8):925–74. Chan RKW, Chio MTW, Koh Y. Manifestaciones cutáneas de infección por el VIH [Internet]. Cuarta edi. Bolognia J, Schaffer J, Cerroni L, editors. Dermatología. Madrid: Elsevier Espa8#241;a, S.L.U.; 2018. 1364–1382 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00078-45. Kaye KM. Virus herpes asociado al sarcoma de Kaposi (virus herpes humano de tipo 8) [Internet]. Octava. Bennett J, Dolin R, Blaser M, editors. Mandell, Douglas y Bennett. Enfermedades infecciosas. Principios y práctica. Elsevier Espa8#241;a, S.L.U.; 2016. 1868–1873 p. Available from: http://dx.doi.org/10.1016/B978-84-9022-917-0/00143-86. Cattani P, Cerimele F, Porta D, Graffeo R, Ranno S, Marchetti S, et al. Agespecific seroprevalence of human herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect [Internet]. 2003 Apr 1 [cited 2020 Jul 7];9(4):274–9. Available from: https://pubmed.ncbi.nlm.nih.gov/12667236/7. Angeloni A, Heston L, Uccini S, Sirianni MC, Cottoni F, Masala MV, et al. High Prevalence of Antibodies to Human Herpesvirus 8 in Relatives of Patients with Classic Kaposi’s Sarcoma from Sardinia. J Infect Dis [Internet]. 1998 Jun [cited 2020 Jul 7];177(6):1715–8. Available from: https://pubmed.ncbi.nlm.nih.gov/9607855/8. Mohanna S, Ferrufino JC, Sanchez J, Bravo F, Gotuzzo E. Epidemiological and clinical characteristics of classic Kaposi’s sarcoma in Peru. J Am Acad Dermatol [Internet]. 2005 [cited 2020 Jul 7];53(3):435–41. Available from: https://pubmed.ncbi.nlm.nih.gov/16112349/9. AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clin Infect Dis. 2017;65(8):1316–26.10. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al. SEER Cancer Statistics Review 1975-2007 National Cancer Institute SEER Cancer Statistics Review 1975-2007 National Cancer Institute. Cancer. 2019.11. Instituto Nacional De Salud. Boletín Epidemiológico Semanal -BES-, Colombia 2019. Ministerio de salud. 2019.12. Jiménez K, Martínez JD, Hernández G, Garzón MA, Hormaza N, Lizarazo JI, et al. Three varieties of Kaposi’s sarcoma with gastrointestinal involvement. Rev Colomb Gastroenterol. 2015;30(3):342–613. Downing C, Mendoza N, Sra K. 80 - Virus del herpes humanos [Internet]. Fourth Edi. DermatologÃ-a. Elsevier Espa8#241;a, S.L.U.; 2019. 1400–1424 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00080-214. Sternbach G, Varon J. Moritz Kaposi: Idiopathic pigmented sarcoma of the skin. J Emerg Med [Internet]. 1995 [cited 2020 Jul 8];13(5):671–4. Available from: https://pubmed.ncbi.nlm.nih.gov/8530789/15. North PE. Neoplasias y proliferaciones seudoneoplásicas vasculares [Internet]. Cuarta edi. Bolognia J, Schaffer J, Cerroni L, editors. Dermatología. Madrid: Elsevier Espa8#241;a, S.L.U.; 2018. 2020–2049 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-365-0/00114-516. Antman K, Chang Y. Kaposi ’s Sarcoma. N Engl J Med. 2000;342(14):1027– 3817. Cai Q, Verma SC, Lu J, Robertson ES. Molecular Biology of Kaposi’s Sarcoma-associated Herpesvirus and Related Oncogenesis [Internet]. 1st ed. Vol. 78, Advances in Virus Research. Elsevier Inc.; 2010. 87–142 p. Available from: http://dx.doi.org/10.1016/B978-0-12-385032-4.00003-318. Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol. 2019;58(5):538–4219. Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation [Internet]. Vol. 42, Seminars in Oncology. W.B. Saunders; 2015 [cited 2020 Jul 12]. p. 247–57. Available from: https://pubmed.ncbi.nlm.nih.gov/25843729/20. Corey C. Virology, epidemiology, and transmission of human herpesvirus 8 infection - UpToDate [Internet]. Uptodate. [cited 2020 Jul 12]. Available from: https://www-uptodate-com.aure.unab.edu.co/contents/virology-epidemiologyand-transmission-of-human-herpesvirus-8-infection?search=sarcoma de kaposi&topicRef=7726&source=see_link21. Krown S, Chadha J. Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis - UpToDate [Internet]. Uptodate. 2019 [cited 2020 Jul 12]. Available from: https://www-uptodatecom.aure.unab.edu.co/contents/classic-kaposi-sarcoma-epidemiology-riskfactors-pathology-and-molecular-pathogenesis?search=sarcoma de kaposi&topicRef=7729&source=see_link22. Schneider JW, Dittmer DP. Diagnosis and Treatment of Kaposi Sarcoma [Internet]. Vol. 18, American Journal of Clinical Dermatology. Springer International Publishing; 2017 [cited 2020 Jul 8]. p. 529–39. Available from: /pmc/articles/PMC5509489/?report=abstract23. Kandemir NO, Gun BD, Bahadir B, Yurdakan G, Ozdemir N, Karadayi N, et al. C-Kit (CD117) expression in classic Kaposi’s sarcoma: Experimental dermatology. Clin Exp Dermatol [Internet]. 2010 Jul [cited 2020 Jul 12];35(5):525–30. Available from: https://pubmed.ncbi.nlm.nih.gov/1987436124. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol [Internet]. 2008 May [cited 2020 Jul 7];21(5):572–82. Available from: https://pubmed.ncbi.nlm.nih.gov/18376387/25. Requena C, Alsina M, Morgado-Carrasco D, Cruz J, Sanmartín O, SerraGuillén C, et al. Kaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment. Actas Dermosifiliogr [Internet]. 2018;109(10):878–87. Available from: https://doi.org/10.1016/j.ad.2018.06.01326. Montagnino G, Bencini PL, Tarantino A, Caputo R, Ponticelli C. Clinical features and course of kaposi’s sarcoma in kidney transplant patients: Report of 13 cases. Am J Nephrol [Internet]. 1994 [cited 2020 Jul 15];14(2):121–6. Available from: https://pubmed.ncbi.nlm.nih.gov/8080004/27. Shepherd FA, Maher E, Cardella C, Cole E, Greig P, Wade JA, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol [Internet]. 1997 [cited 2020 Jul 15];15(6):2371–7. Available from: https://pubmed.ncbi.nlm.nih.gov/919615228. Groopman J. AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis - UpToDate [Internet]. Uptodate. 2018 [cited 2020 Jul 15]. Available from: https://www-uptodate-com.aure.unab.edu.co/contents/aids-relatedkaposi-sarcoma-clinical-manifestations-and-diagnosis?search=sarcoma de kaposi&topicRef=7729&source=see_link29. Ackerman AB. Subtle clues to diagnosis by conventional microscopy. The patch stage of Kaposi’s sarcoma. Am J Dermatopathol [Internet]. 1979 [cited 2020 Jul 18];1(2):165–72. Available from: https://pubmed.ncbi.nlm.nih.gov/549492/30. O’Donnell PJ, Pantanowitz L, Grayson W. Unique histologic variants of cutaneous Kaposi sarcoma. Am J Dermatopathol [Internet]. 2010 May [cited 2020 Jul 18];32(3):244–50. Available from: https://pubmed.ncbi.nlm.nih.gov/20075709/31. Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol [Internet]. 2008 [cited 2020 Jul 18];3(1). Available from: https://pubmed.ncbi.nlm.nih.gov/18655700/32. Pak F, Pyakural P, Kokhaei P, Kaaya E, Pourfathollah AA, Selivanova G, et al. HHV-8/KSHV during the development of Kaposi’s sarcoma: Evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol [Internet]. 2005 Jan [cited 2020 Jul 18];32(1):21–7. Available from: https://pubmed.ncbi.nlm.nih.gov/15660651/33. Bishop BN, Lynch DT. Cancer, Kaposi Sarcoma [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2020 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3052126034. Bishop BN, Lynch DT. Cancer, Kaposi Sarcoma [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2020 Nov 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3052126035. Marušić Z, Billings SD. Histopathology of Spindle Cell Vascular Tumors [Internet]. Vol. 10, Surgical Pathology Clinics. W.B. Saunders; 2017 [cited 2020 Aug 18]. p. 345–66. Available from: https://pubmed.ncbi.nlm.nih.gov/2847788536. Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, et al. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of african children: Evidence for at least 2 patterns of KSHV transmission. J Infect Dis [Internet]. 2009 Aug 1 [cited 2020 Aug 18];200(3):430–8. Available from: /pmc/articles/PMC3975590/?report=abstract37. Moosa MR. Kaposi’s sarcoma in kidney transplant recipients: A 23-year experience. QJM - Mon J Assoc Physicians [Internet]. 2005 Mar [cited 2020 Aug 18];98(3):205–14. Available from: https://pubmed.ncbi.nlm.nih.gov/1572840238. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS [Internet]. 2009 Aug 24 [cited 2020 Aug 18];23(13):1701–6. Available from: https://pubmed.ncbi.nlm.nih.gov/1955028339. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy. Cancer [Internet]. 2010 Aug 15 [cited 2020 Aug 18];116(16):3969–77. Available from: https://pubmed.ncbi.nlm.nih.gov/2056416240. Delyon J, Bizot A, Battistella M, Madelaine I, Vercellino L, Lebbé C. PD-1 blockade with nivolumab in endemic Kaposi sarcoma [Internet]. Vol. 29, Annals of Oncology. Oxford University Press; 2018 [cited 2020 Aug 18]. p. 1067–9. Available from: https://pubmed.ncbi.nlm.nih.gov/2932499541. Lundgren JD, Melbye M, Pedersen C, Rosenberg PS, Gerstoft J. Changing patterns of kaposi’s sarcoma in danish acquired immunodeficiency syndrome patients with complete follow-up. Am J Epidemiol [Internet]. 1995 Apr 1 [cited 2020 Nov 18];142(7):652–8. Available from: https://pubmed.ncbi.nlm.nih.gov/7702040/42. Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi’s sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol [Internet]. 1993 [cited 2020 Nov 18];28(3):371– 95. Available from: https://pubmed.ncbi.nlm.nih.gov/844505443. Franceschi S, Arniani S, Balzi D, Geddes M. Survival of classic Kaposi’s sarcoma and risk of second cancer. Br J Cancer. 1996;74(11):1812–4.44. Tam HK, Zhang ZF, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer. 2002;98(6):916–22.45. Lodi S, Guiguet M, Costagliola D, Fisher M, De Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102(11):784–9246. Sen F, Tambas M, Ciftci R, Toz B, Kilic L, Bozbey HU, et al. Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma. J Dermatolog Treat. 2016;27(3):275–7.47. Royse KE, El Chaer F, Amirian ES, Hartman C, Krown SE, Uldrick TS, et al. Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. PLoS One. 2017;12(8):1–1248. Vivek K, Parita S, Mohit G, Arsalan T, Abhinav B. Racial disparities in incidence & survival of Kaposi’s sarcoma in the United States Vivek. Indian J Med Res [Internet]. 2019;354–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2314449049. Saldarriaga-Cantillo A, Bravo LE, Londoño Ó, García LS, Collazos P. Epidemiological surveillance of the HIV/AIDS complex through the analysis of trends in the incidence of Kaposi’s sarcoma in Cali, Colombia. Colomb Med. 2012;43(4):273–8050. Levi F. Cancer incidence in five continents, vol. VI. Vol. 29, European Journal of Cancer. 1993. 2315–2319 p51. Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Collazos T, et al. Reliable information for cancer control in Cali, Colombia. Colomb Med [Internet]. 2018 [cited 2021 Jun 8];49(1):23–34. Available from: /pmc/articles/PMC6018818/52. Mohanna S, Maco V, Bravo F, Gotuzzo E. Epidemiology and clinical characteristics of classic Kaposi’s sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: A critical review of an old disease [Internet]. Vol. 9, International Journal of Infectious Diseases. Elsevier; 2005 [cited 2020 Jul 7]. p. 239–50. Available from: https://pubmed.ncbi.nlm.nih.gov/1609594053. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: A clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol. 2008;21(5):572–8254. Oncologia C. Survival and Prognostic Factors of Kaposi ’ s Sarcoma Patients Treated at a High Complexity Oncology Care Center. 2020;66(3).55. Klingenberg RE, Esser S, Brockmeyer NH, Michalik C, Skaletz-Rorowski A, Potthoff A. Profile of Kaposi sarcoma patients in the competence network HIV/AIDS. Hautarzt. 2018;69(2):143–8.56. Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S, et al. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32(5):409–14LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repository.unab.edu.co/bitstream/20.500.12749/13926/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53open accessORIGINAL2021_Tesis_Pedro_Diaz_Bueno.pdf2021_Tesis_Pedro_Diaz_Bueno.pdfTesisapplication/pdf662578https://repository.unab.edu.co/bitstream/20.500.12749/13926/1/2021_Tesis_Pedro_Diaz_Bueno.pdf4edca90cce0e81169e3ecfd61ee3d8b9MD51open access2021_Licencia_Pedro_Diaz_Bueno.pdf2021_Licencia_Pedro_Diaz_Bueno.pdfLicenciaapplication/pdf136740https://repository.unab.edu.co/bitstream/20.500.12749/13926/2/2021_Licencia_Pedro_Diaz_Bueno.pdf0ea3378defa5bdb0a3f5588784c69c56MD52metadata only accessTHUMBNAIL2021_Tesis_Pedro_Diaz_Bueno.pdf.jpg2021_Tesis_Pedro_Diaz_Bueno.pdf.jpgIM Thumbnailimage/jpeg5240https://repository.unab.edu.co/bitstream/20.500.12749/13926/4/2021_Tesis_Pedro_Diaz_Bueno.pdf.jpgfcf0ea29c4b8ed925a8c493087419146MD54open access2021_Licencia_Pedro_Diaz_Bueno.pdf.jpg2021_Licencia_Pedro_Diaz_Bueno.pdf.jpgIM Thumbnailimage/jpeg9647https://repository.unab.edu.co/bitstream/20.500.12749/13926/5/2021_Licencia_Pedro_Diaz_Bueno.pdf.jpg6389e2ad47659de81a755bc3119e495cMD55open access20.500.12749/13926oai:repository.unab.edu.co:20.500.12749/139262023-03-15 10:23:47.406open accessRepositorio Institucional | Universidad Autónoma de Bucaramanga - UNABrepositorio@unab.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=